0
Diffuse Lung Disease: Diffuse Lung Disease: Interstitial Lung Disease |

The Effection of Low Dose rhGM-CSF Subcutaneously for PAP FREE TO VIEW

Fen Zhang; Ying Zhou; Jinfu Xu; Huiping Li
Author and Funding Information

Shanghai Pulmonary Hospital, Shanghai, China


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;149(4_S):A217. doi:10.1016/j.chest.2016.02.224
Text Size: A A A
Published online

SESSION TITLE: Diffuse Lung Disease: Interstitial Lung Disease

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: There are many studies show that subcutaneous injection or inhalation rhGM-CSF treatment for autoimmune pulmonary alveolar proteinosis is effective, but the drug dose is large, if we can reduce the dose for the same effection, the dverse reactions and the economic burden could be greatly cutten back.

METHODS: Screening From July 2011 to December 2014 in Shanghai Pulmonary Hospital,24 cases diagnosed with autoimmune PAP patients were included in this study (Clinical Research Register), the GM-CSF antibody titers was detected before the treatment of GM-CSF, outcome measures includes clinical Symptoms, 6-minute walk test and chest CT and so on. The patients was administered 1.25ug / kg / d GM-CSF qd the first month, as the assessment is valid, then continue to give 1.25ug / kg / d qd GM-CSF subcutaneously for next two months, and then 1.25ug / kg / d GM-CSF qod for three months.

RESULTS: six patients completed 6 months of treatment were observed, the results suggest that low-dose rhGM-CSF for the treatmentof PAP is effective, the mean ± standard of dyspnea score before and after treatment using the t test statistically were (4.17 ± 0.75) and (2.50 ± 1.38) (p = 0.011); 6-minute walk distance was improved after treatment, the mean ± standard were (344 ± 107) and (433 ± 81) (p = 0.027); chest CT lesions also prompted significant absorption, the mean ± standard of its proportion of ground-glass opacity scores before and after the treatment were (4.67 ± 0.52) and (2.83 ± 1.83) (p = 0.038).

CONCLUSIONS: Low-dose rhGM-CSF subcutaneously for patients with autoimmune PAP is effective, but still need larger sample trials to be confirmed.

CLINICAL IMPLICATIONS: If we can reduce the dose for the same effection, the dverse reactions and the economic burden could be greatly cutten back.

DISCLOSURE: The following authors have nothing to disclose: Fen Zhang, Ying Zhou, Jinfu Xu, Huiping Li

No Product/Research Disclosure Information


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543